MSX US Stock Daily Observation: Walmart FY2027 Q2 Earnings Report: Revenue and Profit Beat Expectations, US Same-Store Growth Hits Over Six-Year Low

Odaily星球日报Publicado a 2026-08-21Actualizado a 2026-08-21

Resumen

Walmart's FY2027 Q2 earnings report presents a mixed picture. While revenue of $187.9B and adjusted EPS of $0.81 both surpassed consensus estimates, a significant slowdown in the core U.S. business dominated the narrative. U.S. comparable store sales grew only 2.6%, the lowest rate in over six years, missing expectations of 3.5%. The company attributed approximately 125 basis points of this drag to pharmacy price deflation. Despite the weak comps, high-margin segments showed robust growth: global e-commerce rose 23%, global advertising jumped 38%, and the U.S. third-party marketplace surged 52%. Adjusted operating profit growth of 17.4% also outpaced revenue growth, indicating improving profitability. The company raised its full-year guidance for net sales and adjusted EPS. However, the upper end of the new EPS guidance range ($2.87) remains below the market consensus ($2.90). This, coupled with the slowing U.S. comps, signals that growth momentum may be easing. The report highlights a shift in consumer behavior towards more cautious spending, even as transaction volumes remain stable. The key question going forward is whether the rapid expansion of high-margin, non-retail businesses can sufficiently offset the deceleration in core retail growth.

【MSX Research Institute · US Stock RWA Daily Observation】 is a flagship daily report produced by MSX, a leading RWA trading platform. Leveraging our robust macroeconomic research capabilities, we capture the core pulse of the global traditional US stock market, liquidity changes, and the RWA tokenization market to help you strategically position in quality assets.

Today's Observation

Walmart's revenue and adjusted earnings per share (EPS) both beat expectations for the quarter. However, same-store sales growth in its core US market decelerated to its slowest pace in over six years, with pharmacy price deflation being the primary drag. The company raised its full-year sales and profit guidance, but the upper limit of the revised EPS guidance still fell short of market consensus, with signals of slowing growth momentum overshadowing the quarterly beat.

Data at a Glance

FY2027 Q2 total revenue reached $187.9 billion, up 5.9% year-over-year, beating the consensus estimate of $186.77 billion.

Adjusted EPS was $0.81, up 19% year-over-year, beating the consensus of $0.74; but GAAP net income attributable to Walmart was $6.37 billion, down 9% year-over-year, showing divergence between the two measures.

US same-store sales grew only 2.6%, missing the consensus of 3.5% and marking the slowest growth in over six years; the company attributed pharmacy price deflation as a drag of approximately 125 basis points.

By segment: Walmart US net sales were $125.2 billion, up 3.5% YoY; International net sales were $35.2 billion, up 13% YoY; Sam's Club (US) net sales were $25.7 billion, up 8.8% YoY, with comparable sales excluding fuel up 4.4%.

High-margin businesses maintained strong growth: Global e-commerce grew 23% (US +24%); Global advertising grew 38% (Walmart Connect +43%); US third-party marketplace sales grew 52%.

Adjusted operating income was $9.2 billion, up 17.4% on a constant currency basis, outpacing revenue growth.

Full-year guidance was raised across the board: Net sales growth guidance raised from 3.5%-4.5% to 4.0%-5.0%; Adjusted EPS guidance raised to $2.80-$2.87 (from $2.75-$2.85 previously); Adjusted operating income growth guidance is 7.0%-8.5%.

However, the raised EPS guidance upper limit of $2.87 still falls short of the consensus of $2.90. The company noted it has begun receiving tariff refunds this quarter and committed to using these funds to lower product prices.

MSX View

The contradiction in this earnings report lies in the fact that almost every quarterly figure exceeded expectations, while the issues lie in the structure and forward outlook. Revenue, adjusted profit, and operational efficiency all showed improvement: adjusted operating profit growth outpaced revenue growth, and high-margin businesses like advertising, third-party marketplace, and e-commerce all grew at double-digit or higher rates, indicating an improvement in Walmart's profit quality.

US same-store sales growth slowing to a more than six-year low of 2.6% brings the narrative back to a fundamental question: As the broadest-coverage US retailer, its same-store data is a thermometer for consumer health. Pharmacy price deflation explains about 125 basis points, with the remainder pointing to actual changes in consumer behavior. Stable transaction counts but declining average ticket size mean shoppers are still coming, but spending more cautiously.

The fact that full-year guidance was raised across the board yet still fell short of expectations precisely illustrates that market growth expectations for this company have run ahead of the company's own projections. The key going forward is whether the expansion pace of high-margin, non-retail businesses can remain sufficiently strong to offset the slowdown in core retail growth.

About MSX

MSX is a leading RWA trading platform committed to providing secure, efficient, and transparent access to global financial markets. As one of the world's earliest on-chain US stock trading platforms, MSX has consistently been at the forefront of the industry, driving market evolution through continuous innovation.

The platform deeply integrates blockchain technology with compliance frameworks, offering comprehensive trading in spot and derivatives for nearly 400 tokenized stocks and Pre-IPO assets, perfectly bridging the gap between traditional finance and the digital asset industry.

Centered around the core mission of "enabling the free flow of quality assets," MSX has now built a diversified digital financial services ecosystem encompassing US stock spot & perpetual contracts, crypto-to-crypto trading, Pre-IPO, and the MSX Research Institute, aiming to provide global investors with a round-the-clock, high-performance gateway to quality assets.

Official Website: https://msx.com/

Chinese TG:https://t.me/MSXOfficial

Global TG:https://t.me/MSXGlobal

X:https://x.com/MSX_CN

Now available globally on App Store and Google Play.

Risk Warning: Macroeconomic and US stock market volatility is intense. The content of this article is for academic and research observation reference by the MSX Research Institute only and does not constitute any investment advice.

Criptos en tendencia

Preguntas relacionadas

QDid Walmart's revenue and adjusted earnings exceed or fall short of expectations in FY2027 Q2?

AIn FY2027 Q2, Walmart's revenue and adjusted earnings per share both exceeded market expectations.

QWhat was the key disappointing metric in Walmart's US performance for the quarter, and what was cited as the primary reason for it?

AThe key disappointing metric was US comparable store sales growth, which was only 2.6%, its lowest level in over six years. The company cited pharmacy price deflation as the primary reason, dragging it down by approximately 125 basis points.

QWhich high-margin segments of Walmart's business continued to show strong growth according to the report?

AHigh-margin segments showing strong growth included global e-commerce (up 23%), global advertising business (up 38%), and US third-party marketplace sales (up 52%).

QHow did Walmart revise its full-year guidance following the Q2 results, and did it meet market expectations?

AWalmart revised its full-year guidance upwards for net sales growth and adjusted EPS. However, the upper end of the adjusted EPS guidance ($2.87) still fell short of the market consensus expectation of $2.90.

QAccording to the MSX View analysis, what is the fundamental concern about Walmart's future growth despite the strong quarterly numbers?

AThe fundamental concern is the slowdown in core retail growth, as indicated by the multi-year low in US comparable sales. The future key is whether the expansion speed of high-margin non-retail businesses can continue to be fast enough to offset this core retail slowdown.

Lecturas Relacionadas

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbitHace 19 min(s)

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbitHace 19 min(s)

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbitHace 20 min(s)

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbitHace 20 min(s)

Trading

Spot

Artículos destacados

Cómo comprar BEAT

¡Bienvenido a HTX.com! Hemos hecho que comprar Audiera (BEAT) sea simple y conveniente. Sigue nuestra guía paso a paso para iniciar tu viaje de criptos.Paso 1: crea tu cuenta HTXUtiliza tu correo electrónico o número de teléfono para registrarte y obtener una cuenta gratuita en HTX. Experimenta un proceso de registro sin complicaciones y desbloquea todas las funciones.Obtener mi cuentaPaso 2: ve a Comprar cripto y elige tu método de pagoTarjeta de crédito/débito: usa tu Visa o Mastercard para comprar Audiera (BEAT) al instante.Saldo: utiliza fondos del saldo de tu cuenta HTX para tradear sin problemas.Terceros: hemos agregado métodos de pago populares como Google Pay y Apple Pay para mejorar la comodidad.P2P: tradear directamente con otros usuarios en HTX.Over-the-Counter (OTC): ofrecemos servicios personalizados y tipos de cambio competitivos para los traders.Paso 3: guarda tu Audiera (BEAT)Después de comprar tu Audiera (BEAT), guárdalo en tu cuenta HTX. Alternativamente, puedes enviarlo a otro lugar mediante transferencia blockchain o utilizarlo para tradear otras criptomonedas.Paso 4: tradear Audiera (BEAT)Tradear fácilmente con Audiera (BEAT) en HTX's mercado spot. Simplemente accede a tu cuenta, selecciona tu par de trading, ejecuta tus trades y monitorea en tiempo real. Ofrecemos una experiencia fácil de usar tanto para principiantes como para traders experimentados.

903 Vistas totalesPublicado en 2026.01.22Actualizado en 2026.06.02

Cómo comprar BEAT

Discusiones

Bienvenido a la comunidad de HTX. Aquí puedes mantenerte informado sobre los últimos desarrollos de la plataforma y acceder a análisis profesionales del mercado. A continuación se presentan las opiniones de los usuarios sobre el precio de BEAT (BEAT).

活动图片